Rademikibart for Eczema: Monthly Phase 2 Dosing and the 2026 Phase 3 Update Need Separate Denominators
DOCTOR’S NOTES · ECZEMA EVIDENCE
An injection interval can matter to a person planning work travel or family activities. But a monthly regimen in one eczema trial cannot be combined with a one-year response percentage from another study as though both describe the same group. Rademikibart’s evolving evidence makes that distinction particularly important.
The published phase 2 comparison
The April 2024 primary report randomized 226 adults with moderate-to-severe atopic dermatitis to three rademikibart regimens or placebo. Following a 600-mg loading dose, investigators compared 300 mg every two weeks, 150 mg every two weeks and 300 mg every four weeks over 16 weeks.
| Phase 2 regimen | Mean EASI percentage change at week 16 |
|---|---|
| 300 mg every two weeks | −63.0% |
| 150 mg every two weeks | −57.6% |
| 300 mg every four weeks | −63.5% |
| Placebo | −39.7% |
All three primary comparisons with placebo were statistically significant. These are mean severity-score changes, not proportions with clear skin. Similar-looking active-group averages do not by themselves establish formal equivalence between dosing intervals. The trial was funded by Connect Biopharma.
What changed in the 2026 update?
Connect’s March 30, 2026 announcement describes partner-conducted RADIANT-AD research in 259 adolescents and adults in China. Its 16-week induction compared 300 mg every two weeks with placebo; placebo participants then switched to active treatment. The announcement frames week-52 maintenance findings among week-16 responders.
That company announcement reports conference findings; it is not the same source or population as the earlier peer-reviewed phase 2 paper. Its favorable late percentages must retain the responder-selection and switch information. They should not be attached to the older every-four-week regimen or presented as an unchanged placebo-controlled result over a full year.
Three questions before sharing a dosing headline
First, which trial supplied the interval? Second, who is included in the displayed percentage: everyone randomized, everyone with observed data or selected early responders? Third, was the comparison still randomized at that time? A summary that omits those answers can sound more definitive than the underlying design.
A direct equivalence claim would need appropriate prespecified methods and uncertainty estimates. A numerical resemblance is not enough. Likewise, a trial’s injection schedule is a research regimen rather than personal dosing advice, and a conference announcement does not itself establish a medicine’s current local authorization or availability.
Use convenience as one part of a care discussion
Explain which activities or appointments are difficult to coordinate and ask the treating clinician which established options fit both medical needs and practical constraints. Include monitoring, follow-up and what will happen if control remains inadequate. The most convenient-looking schedule in a headline may not be the appropriate plan for an individual.
AAD eczema guidance supplies the broader clinical reference. This article compares the evidence formats; it does not recommend changing an injection interval.
Why separate placebo groups and an open extension also matter for telazorlimab
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.